Loading organizations...
§ Private Profile · City of Orange, USA
SurgiQuest is a technology company.
SurgiQuest develops advanced technology for minimally invasive surgical procedures, centered on its proprietary AirSeal System. This innovative 3-in-1 insufflation management platform maintains a stable pneumoperitoneum, provides continuous smoke evacuation, and allows valve-free access during laparoscopy. By creating an "air curtain," the system optimizes the surgical environment, ensuring an unobstructed view and consistent abdominal cavity pressure throughout complex operations.
The company was founded in May 2006 by Kurt Azarbarzin, who served as its Chief Executive Officer. Azarbarzin’s vision aimed to address critical limitations in traditional minimally invasive surgery, specifically the challenges associated with maintaining a stable and clear operating field. His entrepreneurial drive led to the development of the AirSeal system, which significantly improved the consistency and safety of laparoscopic access.
SurgiQuest’s technology is employed by surgeons across a wide range of specialties, including urology, gynecology, colorectal, and general surgery. The company's overarching mission is to enhance the efficacy and expand the applicability of minimally invasive techniques by providing superior surgical field management. This commitment allows medical professionals to perform intricate procedures with greater precision and improved patient outcomes.
SurgiQuest has raised $64.5M across 4 funding rounds.
SurgiQuest has raised $64.5M in total across 4 funding rounds.
SurgiQuest is a medical technology company that develops and markets innovative access technologies for robotic and laparoscopic surgery, focusing on minimally invasive surgery (MIS) solutions like the proprietary AirSeal® System. This system features a valve-free trocar design that eliminates traditional seals and duckbill valves, enabling stable pneumoperitoneum, continuous smoke evacuation, and use of non-cylindrical instruments, while improving perioperative efficiency for surgeons and patient stability for anesthesia teams[1][2][3]. Incorporated in 2006 and headquartered in Connecticut, the company raised $92M before being acquired, serving hospitals and surgical teams performing procedures such as hysterectomies, addressing longstanding issues like scope smudging, seal failures, and insufflation instability in MIS[1][2].
SurgiQuest was founded in 2006 in Connecticut by executives with deep roots in surgical innovation, many hailing from United States Surgical Corporation, a pioneer in stapling and laparoscopy[1][3]. The idea emerged from frustration with conventional trocars plagued by circular seals and duckbill valves since the 1990s, which caused hassles like scope smudging, fragmented specimen removal, and seal disintegration. Early development pivoted to a revolutionary valve-free trocar, necessitating a new insufflation control unit for circulatory flow that maintained stable pneumoperitoneum and evacuated surgical smoke—unlocking benefits like fearless operation during challenging scenarios (e.g., colpotomy) and easier patient ventilation[1]. Pivotal traction came post-launch as surgeons adopted it for robotic and laparoscopic procedures, validating its transformative potential[1][3].
SurgiQuest rides the wave of expanding minimally invasive surgery (MIS), driven by demand for robotic-assisted procedures that reduce recovery times and complications amid aging populations and rising surgical volumes. Its timing capitalized on post-2000s laparoscopy maturation, addressing unmet needs in pneumoperitoneum stability amid growing robotic adoption (e.g., hysterectomy, general surgery)[1][2]. Market forces like FDA-cleared innovations and competition from peers (e.g., Advanced Surgical Concepts' single-incision devices) favor its circulatory flow tech, influencing the ecosystem by enabling complex MIS without traditional limitations and inspiring ancillary tools for smoke management and instrument versatility[1][2][3].
Post-acquisition, SurgiQuest's AirSeal® technology is poised for wider integration into robotic platforms, fueled by MIS growth and trends like AI-enhanced visualization and outpatient procedures. Evolving regulations and post-pandemic surgical backlogs will amplify demand for efficiency boosters like stable insufflation. Its influence may expand through acquirer scaling, shaping standards for valve-free access and patient-centric MIS—echoing its founding vision that future surgery demands past-rejecting tech[1][2].
SurgiQuest has raised $64.5M in total across 4 funding rounds.
SurgiQuest's investors include Ares Capital Corporation, Aphelion Capital, Fifth Wall, Aphelion, California Technology Ventures, CMEA Capital, Fletcher Spaght Ventures, River Cities Capital Funds.
SurgiQuest has raised $64.5M across 4 funding rounds. Most recently, it raised $18.5M Debt / Series D in December 2012.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 5, 2012 | $18.5M Debt Financing | Ares Capital Corporation | — | Announced |
| Dec 1, 2012 | $8M Series D | — | Aphelion Capital, Fifth Wall | Announced |
| Jul 9, 2011 | $19M Venture Round | — | Aphelion, California Technology Ventures, CMEA Capital, Fletcher Spaght Ventures | Announced |
| Jul 1, 2011 | $19M Series C | River Cities Capital Funds | Aphelion Capital, Fifth Wall, California Technology Ventures, CMEA Capital, Fletcher Spaght Ventures | Announced |